Journal: American Journal of Translational Research

Article Title: Renal and cerebral RAS interaction contributes to diabetic kidney disease

doi:

Figure Lengend Snippet: Renal RAS, oxidative stress, inflammation and glomerulosclerosis were up-regulated in DM rats. A. Representative photographs and semiquantitative data of AGT, AT1 and MCP-1 expression detected by immunohistochemistry (a1) and Western blot (a2). B. Glomerulosclerosis index measured by PAS. C. Protein level of Noxs in renal cortex measured by Western blot. Data are expressed as the mean ± SD (n=15 in each group). *P<0.05 versus non-DM rats. PAS, periodic acid-Schiff.

Article Snippet: Cerebral localization of AGT and AT1 receptors was determined by double-staining immunofluorescence using anti-AGT or anti-AT1 receptors as the first primary antibody, and anti-neuron-specific enolase (Boster Biological Technology, Pleasanton, CA, USA) or anti-glial fibrillary acidic protein (Boster Biological Technology, Pleasanton, CA, USA) as the second primary antibody.

Techniques: Expressing, Immunohistochemistry, Western Blot

Journal: American Journal of Translational Research

Article Title: Renal and cerebral RAS interaction contributes to diabetic kidney disease

doi:

Figure Lengend Snippet: Brain RAS, oxidative stress and sympathetic activity were up-regulated in DM rats. A. AGT and AT1 receptors in SFO (a1), SON (a2) and PVN (a3) measured by immunohistochemistry. B. AGT and AT1 receptors in SFO (b1), SON (b2) and PVN (b3) measured by Western blot. C. Protein levels of NOX2 and NOX4 in SFO (c1), SON (c2) and PVN (c3) measured by Western-blot. D. Representative photographs of TH+c-fos positive cells in RVLM measured by immunohistochemistry. E. Protein levels of TH in RVLM measured by Western-blot. F. Protein levels of TH in SFO, SON, PVN measured by Western-blot. Data are expressed as the mean ± SD (n=15 in each group). *P<0.05 versus Non-DM.

Article Snippet: Cerebral localization of AGT and AT1 receptors was determined by double-staining immunofluorescence using anti-AGT or anti-AT1 receptors as the first primary antibody, and anti-neuron-specific enolase (Boster Biological Technology, Pleasanton, CA, USA) or anti-glial fibrillary acidic protein (Boster Biological Technology, Pleasanton, CA, USA) as the second primary antibody.

Techniques: Activity Assay, Immunohistochemistry, Western Blot

Journal: American Journal of Translational Research

Article Title: Renal and cerebral RAS interaction contributes to diabetic kidney disease

doi:

Figure Lengend Snippet: Localization of central AGT and AT1 receptors and Blood brain barrier permeability. A. Localization of central AGT and AT1 receptors determined by doublestaining with the antibodies against AGT or AT1 receptors (green) and the antibodies-recognized NSE or GFAP (red). NSE, neuron-specific enolase; GFAP, glial fibrillary acidic protein. B. Blood brain barrier permeability was up-regulated in DM rats (b1), but there was no significant difference in all intervention groups (b2).

Article Snippet: Cerebral localization of AGT and AT1 receptors was determined by double-staining immunofluorescence using anti-AGT or anti-AT1 receptors as the first primary antibody, and anti-neuron-specific enolase (Boster Biological Technology, Pleasanton, CA, USA) or anti-glial fibrillary acidic protein (Boster Biological Technology, Pleasanton, CA, USA) as the second primary antibody.

Techniques: Permeability

Journal: American Journal of Translational Research

Article Title: Renal and cerebral RAS interaction contributes to diabetic kidney disease

doi:

Figure Lengend Snippet: Expression of RAS components, NOXs and TH in brain nuclei and kidney measured by western-blot. A. Protein levels of AGT (a1) and AT1 receptors (a2) in brain nuclei measured by Western-blot. B. Protein levels of NOX2 (b1) and NOX4 (b2) in brain nuclei measured by Western-blot. C. Protein expression of TH in SFO, SON PVN (c1) and RVLM (c2) measured by western-blot. D. Protein levels of AGT, AT1, MCP-1 (d1) and Noxs (d2) in renal cortex homogenates measured by Western-blot. Data are expressed as the mean ± SD (n=6 in each group). *P<0.05 versus IG 0 mg/kg/d Los.

Article Snippet: Cerebral localization of AGT and AT1 receptors was determined by double-staining immunofluorescence using anti-AGT or anti-AT1 receptors as the first primary antibody, and anti-neuron-specific enolase (Boster Biological Technology, Pleasanton, CA, USA) or anti-glial fibrillary acidic protein (Boster Biological Technology, Pleasanton, CA, USA) as the second primary antibody.

Techniques: Expressing, Western Blot

Journal: American Journal of Translational Research

Article Title: Renal and cerebral RAS interaction contributes to diabetic kidney disease

doi:

Figure Lengend Snippet: The central administration of losartan or tempol prevented renal RAS activation. A. The central administration of losartan or tempol prevented renal RAS activation. Representative photographs and semiquantitative data of AGT, AT1 and MCP-1 expression by immunohistochemistry. B. The central administration of losartan or tempol did not prevente glomerularsclerosis, however only oral administration of drugs could alleviate glomerulosclerosis. Representative photographs and semiquantitative data of glomerulosclerosis index were shown by PAS. Data are expressed as the mean ± SD (n=6 in each group). *P<0.05 versus IG 0 mg/kg/d Los. PAS, periodic acid-Schiff.

Article Snippet: Cerebral localization of AGT and AT1 receptors was determined by double-staining immunofluorescence using anti-AGT or anti-AT1 receptors as the first primary antibody, and anti-neuron-specific enolase (Boster Biological Technology, Pleasanton, CA, USA) or anti-glial fibrillary acidic protein (Boster Biological Technology, Pleasanton, CA, USA) as the second primary antibody.

Techniques: Activation Assay, Expressing, Immunohistochemistry